Communiqués Recursion Pharmaceuticals, Inc.

Actions

RXRX

US75629V1044

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/09/2026			Après clôture 22:43:59
3,215 ^USD	-6,54%		3,215	0,00%

17/08	Contineum, Disc Medicine et Recursion font progresser leurs portefeuilles de produits avant des catalyseurs clés, selon Morgan Stanley	MT
17/08	Recursion Pharmaceuticals, Inc. : Morgan Stanley maintient sa recommandation neutre	ZM

Communiqués

05/08	Recursion Pharmaceuticals: Q2 Earnings Snapshot	AQ
05/08	Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program	GL
04/08	Recursion to Participate in Upcoming Investor Conferences	GL
04/08	Recursion to Participate in Upcoming Investor Conferences	AQ
31/07	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules	GL
29/07	Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th	GL
02/06	Recursion to Participate in Upcoming Investor Conferences	GL
29/05	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules	GL
06/05	Recursion Pharmaceuticals: Q1 Earnings Snapshot	AQ
06/05	Recursion Reports First Quarter Financial Results and Provides Business Update	GL
01/05	Recursion Pharmaceuticals : 2026 Proxy Statement	PU
30/04	Recursion Announces Board Transition	GL
29/04	Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6	GL
07/04	Recursion to Participate in Upcoming Investor Conferences	GL
25/03	Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer	GL
25/03	Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer	AQ
27/02	Recursion Pharmaceuticals : 2025 Shareholder Letter and Business Overview	PU
25/02	Recursion Pharmaceuticals: Q4 Earnings Snapshot	AQ
25/02	Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
23/02	Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC	GL
23/02	Recursion to Participate in Upcoming Investor Conferences	GL
18/02	Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25	GL
12/02	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules	GL
06/01	Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference	GL
08/12	Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks	GL